Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$3.60 USD
-0.04 (-1.10%)
Updated Jul 24, 2024 03:54 PM ET
After-Market: $3.61 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DARE 3.60 -0.04(-1.10%)
Will DARE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DARE
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
DARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
Other News for DARE
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Daré Bioscience Regains Nasdaq Compliance, Advances Phase 3 Trials
Dare�� Bioscience regains compliance with Nasdaq's minimum bid price rule
Dare Bioscience regains compliance with Nasdaq minimum bid price rule
Dare Bioscience Inc trading halted, news pending